[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"skeletal-muscle-atrophy\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:skeletal-muscle-atrophy":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,41],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100535536","changes-in-skeletal-muscle-thickness-in-patients-with-acute-heart-failure-100535536",false,"NCT06253104","Changes in Skeletal Muscle Thickness in Patients With Acute Heart Failure","Inclusion Criteria:\n\n1. Over 18 years of age\n2. Ejection fraction \\\u003C40%\n3. Cardiogenic shock defined by clinical criteria (including any of: lactate \\>2.5 mmol\u002FL, systolic blood pressure \\\u003C90 mmHg, acute kidney or liver injury, or cardiac index \\\u003C2.1 on hemodynamic monitoring) plus the clinical requirement for at least one pressor, inotrope, or temporary mechanical circulatory support device (MCSD)\n\nExclusion Criteria:\n\n1. History of LVAD or other durable ventricular assist device\n2. An identified clinical disorder associated with skeletal muscle weakness\u002Fwasting (e.g., muscular dystrophy, mitochondrial disorder, active cancer, modified Rankin score greater or equal to 4 post-stroke\n3. Chronic enteric and parenteral nutrition support patients\n\nIntubation or prior history of heart transplantation are not exclusion criteria if the inclusion criteria are otherwise met.","ALL","18 Years","100 Years",{"count":19,"type":20},60,"ESTIMATED","OBSERVATIONAL","This study aims to determine, via skeletal muscle ultrasound (US), the extent, timing and relationship between skeletal muscle mass loss and outcomes after orthotropic heart transplantation (OHT) and left ventricular assist device (LVAD) implantation amongst patients with cardiogenic shock. Advanced therapies such as OHT and VADs in the heart failure (HF) population may promote skeletal muscle mass and subsequent quality of life, but there is a lack of literature assessing muscle mass changes in HF patients before and after advanced therapies using US imaging. Therefore this observational study will provide further insight into the 1) changes in lean body mass during critical illness and 2) the feasibility of using bedside US to assess lean body mass in the inpatient setting.",[24,25,26,27],"Heart Failure","Muscle Atrophy","Skeletal Muscle Atrophy","Cardiogenic Shock","RECRUITING","2025-04-18",{"date":31,"type":32},"2025-04-23","ACTUAL",{"date":34,"type":32},"2024-02-19",{"date":36,"type":20},"2026-12-31",{"name":38,"class":39},"Tufts Medical Center","OTHER",1,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":47,"eligibilityCriteria":48,"healthyVolunteers":49,"sex":15,"minAge":16,"maxAge":50,"enrollmentInfo":51,"targetDuration":4,"studyType":53,"phases":54,"briefSummary":56,"conditions":57,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":40},"100560126","resistance-training-detraining-and-retraining-study-2024-tradere2024-100560126","NCT06573086","Resistance Training, Detraining, and Retraining Study 2024 (TraDeRe2024)","Towards Personalized Exercise: Identifying the Determinants of Individual Variation in Repeated Resistance Training (TraDeRe) and Examining Transferability of Responsiveness Between Resistance Training and Endurance Training","TraDeRe","Inclusion Criteria:\n\n* age 18-50\n* healthy (e.g., no diagnosed type 2 diabetes, cardiovascular disease, musculoskeletal disorders, etc.)\n* prior participation in intervention I (NCT05874986)\n\nExclusion Criteria:\n\n* medication affecting the cardiovascular system or metabolism\n* metabolic, musculoskeletal, cardiovascular, or other diseases or disorders which may preclude the ability to perform exercise training and testing",true,"50 Years",{"count":52,"type":20},90,"INTERVENTIONAL",[55],"NA","The goals of our research project are to identify factors explaining inter-individual variation in responses to resistance training (RT) and the baseline determinants underlying an individual's sensitivity to respond to RT. Moreover, investigators aim to assess whether a responsiveness to RT predicts responsiveness to endurance training (ET). Thus, investigators aim to gain a deeper understanding of exercise adaptation processes. The main questions investigators aim to answer are:\n\n* Can the physiological responses of one RT intervention be extrapolated to a subsequent RT intervention?\n* If so, what are the mechanisms underlying differing skeletal muscle growth responses in low, and high responders of skeletal muscle hypertrophy?\n* If so, do the low responders of skeletal muscle growth respond more favourably when the amount of RT is increased?\n* Are the high, moderate, and low responders of RT also the highest, moderate, and lowest responders to ET?\n\nTo examine these main research questions, high (n=30), low (n=30), and moderate (n=30) responders of skeletal muscle growth in response to RT (intervention I, NCT05874986) are reallocated into a subsequent 12-week RT intervention (intervention II) after a detraining period. A subgroup of these participants (n=10) will engage in a 6-week control period before starting the second RT period. Additionally, after intervention II, participants will participate in an ET intervention, lasting 6 weeks.\n\nIn this intervention II, reallocated participants will be:\n\n* Resistance training with supervision for 12 weeks\n* Consuming deuterium oxide for the assessment of muscle protein synthesis\n* Consuming D3-3-methylhistidine for the assessment of acute muscle protein breakdown\n* Consuming D3-creatine for the examination of whole-body skeletal muscle mass\n* Providing a spot urine sample six (6) times, and urine collection for 24 hours performed twice\n* Providing saliva samples (30-32 in total) for the assessment of body water enrichment of deuterium\n* Providing a muscle biopsy four or five (4-5) times during the study\n* Providing a blood sample fourteen (14) times during the study\n* Assessed for body composition and body volume four or five times (4-5) during the study\n* Participating in muscle size, maximal dynamic strength and TMS measurements four or five (4-5) times during the study\n* Asked to answer questionnaires related to e.g. stress, physical activity, sleep, perceived exertion, and diet\n* Participating in recovery measurements before and after the second-to-last and the last RT bout, and once in the days between these RT bouts, consisting of six (6) body volume measurements and six (6) maximal voluntary isometric contraction (kg) tests using horizontal leg press for the assessment of neuromuscular recovery\n* Participating in an acute resistance exercise (RE) after the 12-week RT intervention.\n\nFurthermore, in the ET intervention, participants will be:\n\n* Participating in a familiarization session and resting electrocardiograph measurements before the intervention\n* Participating in endurance testing consisting of body composition, movement economy, and incremental RAMP testing before and after ET intervention\n* Endurance training with supervision for 6 weeks, three times a week.",[58,59,26,60],"Hypertrophy","Exercise Training","Healthy","2025-04-03",{"date":63,"type":32},"2025-04-06",{"date":65,"type":32},"2024-08-19",{"date":67,"type":20},"2025-06-15",{"name":69,"class":39},"University of Jyvaskyla"]